Ontogeny of DCs
DCs originate from hematopoietic stem cells, although their stages of differentiation from progenitors are poorly understood. A myeloid origin has been proposed for these cells, based on their shared responsiveness to GM-CSF with monocytes and granulocytes. A common progenitor has been identified in cultures o f major histocompatibility complex (MHC) class II negative mouse bone marrow cells which, in the presence of GM-CSF, proliferate and dif ferentiate into mixed colonies containing DCs, monocytes and granulocytes [2] . Furthermore, a progenitor has been identified in human bone marrow which can give rise to both DCs and monocytes, indicating that DCs may branch from the mononuclear phagocyte lineage [3] .
Following their departure from the bone marrow, DCs enter the blood and migrate to the tissues. The best characterized tissue DC is the Langerhans cell (LC) of the skin. LCs express Fc .com by on July 26, 2006 receptors (FcRs) which enable these cells to take up antigen specifically. On culturing both human and mouse LCs, however, FcR expression is lost while the expression of MHC class I and II is increased [4, 5] . As demonstrated in the murine system [4] , this correlates with a 10-fold increase in activity in the mixed leukocyte reaction (MLR), which is indicative of their T cell stim ulatory capacity. Based on these findings, a model delineating two main stages of DC matu ration has been proposed. First, immature DCs are capable of taking up and processing antigen, and second, mature DCs are efficient at pre senting antigen to T cells. In vivo tissue-resi dent DCs, such as LCs, could be classed as immature DCs. Following antigen uptake, these cells are mobilized and migrate via the afferent lymph and blood to secondary lymphoid organs where they stimulate T cell responses. The mobi lization of these DCs is concomitant with their differentiation into mature DCs. In order to circumvent the difficulties encountered during the isolation of peripheral blood DCs, methods have been developed for the generation o f DCs in vitro. Starting with either bone marrow or blood cells, murine DCs were generated following culture in the presence of GM-CSF [7, 8] . GM-CSF could similarly be used in the generation o f human DCs, but required in addition tumor necrosis factor a (TNF-a) when starting with CD34+ progenitor cells [9] , and interleukin 4 (IL-4) when starting with peripheral blood [10, 11] , From peripheral blood it has been found that GM-CSF in combi nation with IL-4 results in a yield of DCs which is 40-to 80-fold higher than would normally be expected from peripheral blood [10, 11] . While a small proportion of these cells may arise from proiiferatingprogenitors present in the blood, it is likely that the majority are derived from mono cytes. The relationship between DCs freshly iso lated from peripheral blood to those generated in vitro, either from hematopoietic progenitors or peripheral blood, remains to be established.
Isolation and In Vitro Generation of DCs

DC Phenotype
DCs share many features with mononu clear phagocytes, although there are also clear differences which allow for the identification of DCs by phenotypic and morphological cri teria (Table 1) In vitro studies have shown that human peripheral blood DCs are capable of stimulat ing previously unsensitized CD4+ T cells against a panel of antigens [28] . Antigen-specifíc T cell activation was dependent upon the presence in the starting population o f CD45RA* cells, indicative o f naive T cells, and they retained their antigen specificity after long periods in culture. While DCs were an absolute requirement for the initial sensitiza tion, restimulation of these T cell lines could be achieved using macrophages as APCs instead of DCs. This observation gives credence to the idea that the specialized function o f DCs is to sensitize naive T cells which are then able to interact with other APCs.
While the supremacy o f DCs over other APCs in the priming of CD4+ T cells is undis puted, the mechanisms by which they take up antigen are less clear. When compared to macrophages, DCs are weakly endocytic and do not express the same array of FcRs. However, it has been suggested that DCs use macropinocytosis rather than endocytosis to concentrate antigen intracellularly [29] . Unlike other cell types, DCs appear to be constitutively active for macropinocytosis, thus allowing for the continuous uptake of large volumes of fluid. It is also possible that DCs express some as yet uncharacterized antigen-spe cific receptors. One candidate which has been pro posed is the mannose receptor, which is expressed on in vitro-generated DCs. This molecule has pre viously been associated with the scavenging capac ity of macrophages, but could provide some selectivity for foreign antigens due to its ability to bind glycoproteins expressed predominantly on pathogens [29] . Similarly, the murine mole cule DEC-205, which is homologous to the man nose receptor, has been associated with antigen uptake [13] . It was observed that rabbit antibodies against DEC-205 were presented 100 times more efficiently to rabbit Ig-specific T cell hybridomas than were rabbit antibodies against irrelevant antigens. Until recently, the use of DCs as immunotherapeutic agents has been hampered by their low frequency and difficulties in their isolation, as dis cussed earlier in this review. However, with the development of methods for the generation of DCs in vitro, sizeable numbers of DCs are now avail able and have already become valuable tools in the elucidation of antitumor responses. We have shown that using such DCs, CTL responses against melanoma-associated antigen-derived epitopes can be elicited in vitro, from healthy donor-derived peripheral blood lymphocytes [41] , The next step would be to generate large amounts of DCs in vitro, expose them to antigen and reinfuse them into patients. A lthough this prom ising im m unotherapeutic concept may at the moment be only applicable using broadly expressed antigens in melanoma, a similar approach may be applicable to other solid tumors.
DCs as Inducers of Antitumor Immune Responses
Concluding Remarks
The applicability of DCs in the generation of both MHC class I-and class II-restricted pri mary T cell responses against a variety of anti gens has been demonstrated. However, there are many questions which remain to be answered regarding the function of DCs. In particular, it is still unclear as to what the specific characteris tics are which make DCs so different from other professional APCs. While the search for these answers continues, the exploitation of DCs in the clinical setting is already progressing. Especially promising is their usefulness in the generation of tumor vaccines, a field which will no doubt show rapid developments in the near future.
